Three of the venture investors in publicly held Orexigen Therapeutics are departing the board of directors of the company, Orexigen said Friday, as the firm shuffled its board. Orexigen said that Joseph Lacob, Michael Powell, and Daniel Turner--all early venture investors in the company--are departing, as the company adds Lota S. Zoth, CPA to the board. ZOth was most previously CFO at MedImmune. Lacob is at Kleiner Perkins Caufield & Byers, Powell is at Sofinnova Ventures, and Turner is at Montreux Equity Partners. Three of the firm's venture investors--Louis Bock of Scale Venture Partners, and Eckard Weber and Brian Dovey, both of Domain Ventures, remain on the company's board.